skip to content
Primary navigation

Incruse Ellipta

Drug - Incruse® Ellipta® (umeclidinium) [GlaxoSmithKline]

January 2016

Therapeutic area - COPD

Approval criteria

Patients must meet all of the following criteria:

  • Patient has a diagnosis of COPD AND
  • Patient is age 18 or older AND
  • Patient has tried and failed Spiriva OR has a contraindication to Spiriva as documented in clinical progress notes 

Quantity limit

Patient’s most current body weight must be provided at time of request.

Background information

Incruse Ellipta is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top